Xiaodong Luo

Xiaodong Luo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
ZLZhe Li
Zhe Li
JCJun Chen
Jun Chen
JCJianbo Cheng
Jianbo Cheng
SHSicong Huang
Sicong Huang
YHYingyu Hu
Yingyu Hu
PXPingyi Xu
Pingyi Xu
Objective: To investigate the effect of acupuncture on Parkinson's disease (PD) patients with tremor and its potential neuromechanism by functional magnetic resonance imaging (fMRI). Methods: Forty-one PD patients with tremor were randomly assigned to true acupuncture group (TAG, n = 14), sham acupuncture group (SAG, n = 14) and waiting group (WG, n = 13). All patients received levodopa for 12 weeks. Patients in TAG were acupunctured on DU20, GB20, and the Chorea-Tremor Controlled Zone, and patients in SAG accepted sham acupuncture, while patients in WG received no acupuncture treatment until 12 weeks after the course was ended. The UPDRS II and III subscales, and fMRI scans of the patients' brains were obtained before and after the treatment course. UPDRS II and III scores were analyzed by SPSS, while the degree centrality (DC), regional homogeneity (ReHo) and amplitude low-frequency fluctuation (ALFF) were determined by REST. Results: Acupuncture improved the UPDRS II and III scores in PD patients with tremor without placebo effect, only in tremor score. Acupuncture had specific effects on the cerebrocerebellar pathways as shown by the decreased DC and ReHo and increased ALFF values, and nonspecific effects on the spinocerebellar pathways as shown by the increased ReHo and ALFF values (P < 0.05, AlphaSim corrected). Increased ReHo values were observed within the thalamus and motor cortex of the PD patients (P < 0.05, AlphaSim corrected). In addition, the default mode network (DMN), visual areas and insula were activated by the acupuncture with increased DC, ReHo and/or ALFF, while the prefrontal cortex (PFC) presented a significant decrease in ReHo and ALFF values after acupuncture (P < 0.05, AlphaSim corrected). Conclusions: The cerebellum, thalamus and motor cortex, which are connected to the cerebello-thalamo-cortical (CTC) circuit, were modulated by the acupuncture stimulation to alleviate the PD tremor. The regulation of neural activity within the cognitive brain regions (the DMN, visual areas, insula and PFC) together with CTC circuit may contributes to enhancing movement and improving patients' daily life activities.

15 January 2018 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
ZLZhe Li
Zhe Li
YHYing-Yu Hu
Ying-Yu Hu
CZChun-Ye Zheng
Chun-Ye Zheng
QSQiao-Zhen Su
Qiao-Zhen Su
CAChang An
Chang An
MLMao-Cai Liu
Mao-Cai Liu

1 January 2019 in Molecular Pain
Verified
Journal Article
Open access
PDF file
ZLZhe Li
Zhe Li
JCJun Chen
Jun Chen
YLYuwan Lin
Yuwan Lin
MZMiaomiao Zhou
Miaomiao Zhou
QCQiaodi Cai
Qiaodi Cai
PXPingyi Xu
Pingyi Xu
Background: Restless legs syndrome is an important sleep disturbance in Parkinson’s disease. Restless legs syndrome causes an urge to move the legs accompanying sensations which can be difficult to describe but include aching, burning, tingling, or crawling. However, the underlying pathophysiology of restless legs syndrome in Parkinson’s disease remains unknown and no imaging investigation has been conducted to explore its mechanism to date. Objective: This study is to investigate the brain functional changes in Parkinson’s disease with restless legs syndrome (PD-RLS+) patients using functional magnetic resonance imaging. Methods: Data of functional magnetic resonance imaging were collected from 14 PD-RLS+ patients, 20 Parkinson’s disease without restless legs syndrome (PD-RLS−) patients, as well as 19 normal controls during restless legs syndrome-free periods. Intraregional brain activity was evaluated by regional homogeneity method and compared between each pair of the three groups. Area with significantly altered regional homogeneity between two patient groups was further selected as seed in subsequent functional connectivity analysis. Correlations between clinical variables and the altered regional homogeneity and functional connectivity were then assessed in patient groups. Results: Compared with PD-RLS−, PD-RLS+ had much reduced brain activity in the right precentral gyrus, which was negatively associated with restless legs scores in Parkinson’s disease patients. Comparison between PD-RLS+ and normal controls revealed that brain activities were increased in the left brainstem and reduced in the left lingual, fusiform and inferior occipital gyri, middle cingulate and paracingulate gyri, and supplement motor area. Further functional connectivity analysis between right precentral gyrus and left postcentral/precentral gyri decreased dramatically within PD-RLS+ patients, which were also negatively correlated with restless legs symptoms in patient groups. Conclusion: PD-RLS+ patients showed diminished regional homogeneity and functional connectivity within the precentral and postcentral gyri, which implies that the functional abnormalities in sensorimotor network may disrupt the lateral pain pathway, contributing to restless legs syndrome symptoms in Parkinson’s disease patients. This may provide imaging evidence to explore the pathophysiology of Parkinson’s disease-related restless legs syndrome.

28 October 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
SLShaohua Lyu
Shaohua Lyu
AZAnthony Lin Zhang
Anthony Lin Zhang
XGXinfeng Guo
Xinfeng Guo
JSJingbo Sun
Jingbo Sun
CXCharlie Changli Xue
Charlie Changli Xue
Background: Treatment effect of current pharmacotherapies for migraine is unsatisfying. Discovering new anti-migraine natural products and nutraceuticals from large collections of Chinese medicine classical literature may assist to address this gap.Methods: We conducted a comprehensive search in the Encyclopedia of Traditional Chinese Medicine (version 5.0) to obtain migraine-related citations, then screened and scored these citations to identify clinical management of migraine using oral herbal medicine in history. Information of formulae, herbs and symptoms were further extracted. After standardisation, these data were analysed using frequency analysis and the Apriori algorithm. Anti-migraine effects and mechanisms of actions of the main herbs and formula were summarised.Results: Among 614 eligible citations, the most frequently used formula was chuan xiong cha tiao san (CXCTS), and the most frequently used herb was chuan xiong. Dietary medicinal herbs including gan cao, bai zhi, bo he, tian ma and sheng jiang were identified. Strong associations were constructed among the herb ingredients of CXCTS formula. Symptoms of chronic duration and unilateral headache were closely related with herbs of chuan xiong, gan cao, fang feng, qiang huo and cha. Symptoms of vomiting and nausea were specifically related to herbs of sheng jiang and ban xia.Conclusion: The herb ingredients of CXCTS which presented anti-migraine effects with reliable evidence of anti-migraine actions can be selected as potential drug discovery candidates, while dietary medicinal herbs including sheng jiang, bo he, cha, bai zhi, tian ma, and gan cao can be further explored as nutraceuticals for migraine.

1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SLShaohua Lyu
Shaohua Lyu
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
XGXinfeng Guo
Xinfeng Guo
AZAnthony Lin Zhang
Anthony Lin Zhang
JSJing-Bo Sun
Jing-Bo Sun
XLXiaodong Luo
Xiaodong Luo
Background. The prophylactic effects of Chinese herbal medicine (CHM) for migraine were examined in numerous clinical trials. This review aimed to analyze the effectiveness and safety of CHM as prophylactic treatment of migraine compared to flunarizine. Methods. Nine databases were searched for randomized controlled trials (RCTs) that evaluated effects of CHM for episodic migraine prophylaxis compared to flunarizine, published before March 2019. Results. Thirty‐five RCTs with 2,840 participants met the inclusion criteria, and 31 of them were included in meta‐analyses. The overall meta‐analysis indicated that, when compared to flunarizine, CHM reduced the frequency of migraine attacks at the end of treatment (EoT) (21 studies, mean difference (MD) −1.23, 95% confidence interval (CI) (−1.69, −0.76)) and at the end of follow‐up (EoFU) (five studies, MD −0.96, 95% CI (−1.70, −0.21)). Subgroup analyses based on the treatment duration, follow‐up duration, and the dosage of flunarizine showed that CHM was superior to or comparable with flunarizine in reducing migraine frequency. Similar results were also found for secondary outcomes such as the pain visual analogue scale, migraine duration, responder rate, and acute medication usage. In particular, the studies that used CHM containing herb pairs (Chuan Xiong plus Bai Zhi and Chuan Xiong plus Tian Ma) showed promising results. However, the certainty of this evidence was evaluated as “low” or “very low” using the Grading of Recommendations, Assessment, Development and Evaluations approach. Conclusion. CHM appeared to be comparable with flunarizine in reducing the frequency of episodic migraine attacks in adults at EoT and EoFU and well‐tolerated by participants, regardless of the treatment duration, follow‐up duration, and dosage of flunarizine. Due to the low certainty of the evidence, the suggested promising prophylactic outcomes require higher quality evidence from further rigorous RCTs.

6 July 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
SLShaohua Lyu
Shaohua Lyu
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
XGXinfeng Guo
Xinfeng Guo
AZAnthony Lin Zhang
Anthony Lin Zhang
JSJingbo Sun
Jingbo Sun
XLXiaodong Luo
Xiaodong Luo
Background: Migraine is a prevalent headache disorder with significant impacts on patients' quality of life and economic burden. Chinese herbal medicine (CHM) is commonly prescribed for migraine in China. This review aimed to provide a rigorous evaluation of evidence on the efficacy of oral CHM for migraine and explore the correlation between its effect size and treatment duration.Methods: We searched nine digital databases (PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, AMED, BioMedical Literature, CNKI, CQVIP, and Wanfang Data) from their inceptions to May 2021, with the language being restricted to Chinese and English. Randomized, placebo-controlled trials using oral CHM to treat adult migraine were included. Data screening and extraction were conducted by two independent reviewers. The methodological quality of randomized controlled trials (RCTs) was assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to estimate the effect size using a random effect model, and a robust variance estimation (RVE) model was constructed to explore the correlation between treatment effects and treatment duration. The certainty of the evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation. Publication bias was tested using a funnel plot and Egger's test.Results: A total of 18 RCTs involving 3,015 participants were included. Results of the meta-analyses showed that, at the end of the treatment phase, CHM was more efficacious than placebo in reducing migraine frequency, migraine days, and pain severity, and increasing response rate. Additionally, CHM showed superior effects to placebo in lowering migraine frequency and pain severity at the end of the 4-week follow-up. The RVE model suggested that the benefits of CHM for migraine frequency and pain intensity increased as treatment duration extended. The number of adverse events reported by the CHM and placebo groups was comparable. The certainty of the evidence was graded as “moderate.” No publication bias was detected.Conclusion: Oral CHM appeared to be more efficacious than placebo for reducing migraine frequency and pain severity. Greater treatment effects were associated with longer treatment duration. The oral CHM was well tolerated.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/#recordDetails, identifier: CRD42021270719.